Recombinant Mouse Disintegrin and metalloproteinase domain-containing protein 15 (Adam15)

What is Adam15 and what are its key structural domains?

Adam15 is a member of the ADAM (a disintegrin and metalloproteinase) family of transmembrane cell-surface proteins that play crucial roles in adhesion and proteolytic processing. The protein contains several distinct domains with specific functions:

• Metalloproteinase domain (207-419 aa): Well-conserved with the zinc-binding catalytic site consensus sequence HExxHxxGxxHD. This domain contains three histidine residues that coordinate with zinc, and a glutamic acid residue that acts as a catalytic base .

• Disintegrin-like domain (420-510 aa): Contains 90 amino acids and 15 cysteine residues, showing sequence similarity to snake venom disintegrins. This domain is particularly important for cell-cell and cell-matrix interactions .

• Cysteine-rich domain (511-656 aa): Thought to regulate cell fusion and potentially involved in the activation of latent Adam15 through mechanisms that remain incompletely understood .

To effectively study Adam15 structure, researchers should consider X-ray crystallography and molecular modeling approaches that can provide detailed structural information about domain interactions and conformational changes during ligand binding.

What makes mouse Adam15 structurally unique compared to other ADAM family proteins?

Mouse Adam15, like human ADAM15, contains the distinctive Arg-Gly-Asp (RGD) motif in its disintegrin-like domain, which makes it unique among the ADAM family proteins. This specific characteristic has important functional implications:

• Adam15 is the only member of the ADAM family with this RGD integrin binding motif in its disintegrin-like domain .

• The RGD sequence in Adam15 is followed by an additional cysteine residue that is not present in RGD-type snake venom disintegrins, creating a distinctive structural arrangement .

• This unique motif serves as an integrin ligand binding site, enabling Adam15 to interact with specific integrin receptors that recognize the RGD sequence .

To investigate these unique structural features, site-directed mutagenesis of the RGD motif (e.g., converting it to AGD) can help determine the functional significance of this sequence in cellular assays measuring integrin binding and cell adhesion.

How does the disintegrin-like domain of Adam15 function in integrin binding?

The disintegrin-like domain of Adam15 plays a pivotal role in mediating interactions with integrins through both RGD-dependent and RGD-independent mechanisms:

• RGD-dependent binding: The RGD tripeptide in Adam15 serves as an integrin recognition sequence, particularly for αVβ3 integrin. Conversion of RGD into AGD reduces the protein's potency in inhibiting A375-SM cell adhesion to fibrinogen mediated by αVβ3 .

• RGD-independent binding: Adam15 can also interact with α9β1 integrin through a conserved motif RxxxxxxDLPEF (residues 481-492 in human ADAM15), which is present in all ADAMs except ADAM-10 and ADAM-17 .

• Functional consequences: These interactions allow Adam15 to selectively modulate integrin-mediated cell adhesion and smooth muscle cell migration, with the amino acid sequence in the disintegrin-like loop controlling specificity for particular integrins .

For experimental validation of these binding interactions, researchers should employ techniques such as solid-phase binding assays, cell adhesion assays with integrin-expressing cells, and co-immunoprecipitation studies using recombinant disintegrin-like domains.

What experimental systems are commonly used to study recombinant mouse Adam15?

Researchers investigating recombinant mouse Adam15 typically employ several experimental systems to examine its structure and function:

• Primary cell cultures: Aortic smooth muscle cells (AoSMCs) and endothelial cells from wild-type and Adam15-deficient mice can be used to study Adam15's effects on cell proliferation, apoptosis, migration, and contractility .

• In vitro binding assays: To study Adam15-integrin interactions, researchers use purified recombinant disintegrin-like domains (ddAdam15) in binding assays with various integrin-expressing cell lines .

• Animal models: Adam15-deficient (Adam15-/-) mice can be used to investigate the physiological and pathological roles of Adam15 in vivo, such as in angiotensin II-induced abdominal aortic aneurysm models .

When designing experiments with recombinant mouse Adam15, researchers should ensure proper protein folding and post-translational modifications by choosing appropriate expression systems (mammalian cells preferred over bacterial systems) and validating protein activity before conducting functional studies.

What is the mechanism behind Adam15 deficiency-induced abdominal aortic aneurysm (AAA)?

Adam15 deficiency leads to increased susceptibility to abdominal aortic aneurysm through multiple interconnected mechanisms affecting smooth muscle cell (SMC) function and vascular wall integrity:

• SMC dysfunction pathway: In Adam15-deficient mice, angiotensin II infusion triggers:

  • Decreased SMC proliferation and reduced phosphorylation of ERK1/2 and Akt signaling pathways

  • Increased SMC apoptosis

  • Reduced SMC contractility with decreased levels of contractile proteins (SM22 and αSMC)

  • F-actin depolymerization to G-actin

• THBS1-cofilin signaling axis: Adam15 deficiency results in:

  • Markedly greater increase in thrombospondin 1 (THBS1) in the aortic medial layer and in aortic SMCs

  • Increased slingshot homolog 1 (SSH1) phosphatase activity

  • Cofilin dephosphorylation promoting F-actin depolymerization

  • G-actin accumulation

• Vascular wall changes:

  • Loss of medial SMCs

  • Elastin fragmentation

  • Increased inflammation despite preserved endothelial barrier

These findings are consistent with human AAA specimens, which show reduced ADAM15, elevated THBS1, and loss of medial SMCs . Researchers studying this mechanism should employ both in vivo models (Adam15-/- mice with angiotensin II infusion) and in vitro systems with primary aortic SMCs to validate these pathways.

How can researchers effectively quantify Adam15-mediated effects on smooth muscle cell function?

To accurately measure Adam15's impact on smooth muscle cell function, researchers should employ the following methodological approaches:

Proliferation Assessment:

• BrdU incorporation assay to measure DNA synthesis and cell proliferation rates

• Western blotting to analyze phosphorylation of ERK1/2 and Akt signaling pathways that regulate cell growth

Apoptosis Quantification:

• TUNEL staining for detecting DNA fragmentation in apoptotic cells

• Flow cytometry with Annexin V/PI staining to quantify early and late apoptotic cells

Contractility Measurement:

• In vitro gel contraction assay to assess contractile properties (measured as percentage decrease in gel surface area over time)

• Expression analysis of contractile SMC proteins (SM22 and αSMC) using Western blotting

Cytoskeletal Organization:

• Quantification of F-actin/G-actin ratio to assess actin polymerization state

• Immunofluorescence staining to visualize cytoskeletal organization

Migration Analysis:

• Scratch wound healing assay to measure cell migration rate

• Transwell migration assay to quantify directional cell movement

When designing these experiments, researchers should include appropriate controls (wild-type vs. Adam15-deficient cells) and standardize conditions across experimental groups to ensure reproducibility and reliable quantification.

What approaches can be used to study the interaction between Adam15 and integrins in experimental settings?

Investigating the interaction between Adam15 and integrins requires specialized techniques that can assess binding specificity, affinity, and functional consequences:

Binding Specificity Assays:

• Solid-phase binding assays using purified recombinant Adam15 disintegrin-like domain (ddAdam15) and various integrin subtypes

• Cell adhesion assays comparing wild-type ddAdam15 with mutant versions (e.g., RGD→AGD) to determine the importance of specific motifs

• Competitive inhibition assays using integrin-binding peptides or antibodies

Structural Analysis:

• X-ray crystallography of ddAdam15 alone and in complex with integrin headpieces

• Molecular modeling based on the 3D structure of integrin αVβ3 in complex with RGD-containing peptides to predict binding interfaces

Functional Consequence Assessment:

• Inhibition of cell binding to extracellular matrix proteins (e.g., fibrinogen) in a dose-dependent manner

• Analysis of integrin-mediated signaling pathways following Adam15-integrin interaction

• Cell migration assays in the presence of ddAdam15 to assess functional outcomes

A proposed binding model suggests that the RGD motif of ddAdam15 (R64GD66) fits into a crevice between the propeller (α subunit) and βA (β1 subunit) domains on the β1-associated complex headpiece . Researchers should design experiments to validate this model and explore binding differences between RGD-dependent and RGD-independent interactions.

How does Adam15 regulate the THBS1-cofilin pathway in vascular smooth muscle cells?

Adam15 plays a critical role in regulating the THBS1-cofilin pathway in vascular smooth muscle cells, with significant implications for cytoskeletal organization and cell function:

Regulatory Mechanism:

• Adam15 deficiency leads to upregulation of thrombospondin 1 (THBS1) in aortic smooth muscle cells, particularly following angiotensin II stimulation

• Elevated THBS1 activates the slingshot homolog 1 (SSH1) phosphatase

• SSH1 activation leads to cofilin dephosphorylation (activation)

• Activated cofilin promotes F-actin depolymerization to G-actin

• G-actin accumulation disrupts cytoskeletal organization and impairs cell function

Experimental Evidence:

• Treatment with recombinant THBS1 alone is sufficient to activate the cofilin pathway, increase G-actin, and induce apoptosis in aortic SMCs

• Adam15-deficient AoSMCs show increased G-actin content following angiotensin II treatment

• These changes correlate with reduced contractility and increased apoptosis

This pathway represents a key mechanism through which Adam15 maintains vascular smooth muscle cell function and prevents aortic aneurysm formation. Researchers studying this pathway should use both pharmacological inhibitors and genetic approaches (siRNA, CRISPR-Cas9) to manipulate each component and determine their relative contributions to the observed phenotypes.

What are the contradictions in the literature regarding Adam15's role in vascular inflammation?

The literature presents apparently contradictory findings regarding Adam15's role in vascular inflammation, which require careful consideration when designing research studies:

Contradiction 2: Inflammatory Cell Recruitment

• Adam15 deficiency impairs endothelial migratory ability essential for repairing the endothelial cell barrier, which should theoretically reduce inflammation

• Yet, increased THBS1 in Adam15-deficient vessels promotes adhesion and migration of mononuclear cells, enhancing inflammation

Contradiction 3: Cell-Specific Effects

• Adam15's effects appear to be cell-type specific, with different outcomes in endothelial cells versus smooth muscle cells

• In endothelial cells, Adam15 may promote barrier function

• In smooth muscle cells, Adam15 prevents apoptosis that could otherwise serve as a chemoattractant for inflammatory cells

To resolve these contradictions, researchers should design experiments that:

• Use tissue-specific knockout models to isolate cell-type specific effects

• Employ co-culture systems to study cell-cell interactions

• Analyze temporal dynamics of inflammatory processes following Adam15 manipulation

• Consider the influence of different inflammatory stimuli and pathological contexts

What methods should be used to generate functional recombinant mouse Adam15 for in vitro studies?

Producing functional recombinant mouse Adam15 requires careful consideration of expression systems, purification strategies, and validation methods:

Recommended Expression Systems:

• Mammalian expression systems (HEK293, CHO cells) are preferred over bacterial systems to ensure proper folding and post-translational modifications

• Baculovirus-insect cell systems represent a good alternative for higher yield while maintaining eukaryotic processing

Expression Construct Design:

• Include appropriate tags (His, FLAG) for purification while ensuring they don't interfere with protein function

• Consider expressing specific domains (e.g., disintegrin-like domain) separately for domain-specific studies

• Include proper signal sequences for secretion if producing soluble forms

Purification Strategy:

• Affinity chromatography using tag-based purification

• Size exclusion chromatography to separate aggregates

• Ion exchange chromatography for final polishing

Functional Validation:

• Integrin binding assays to confirm proper folding of the disintegrin-like domain

• Cell adhesion inhibition assays to verify functional activity

• Analysis of effects on smooth muscle cell proliferation, apoptosis, and contractility

Storage Recommendations:

• Store purified protein in small aliquots at -80°C to avoid freeze-thaw cycles

• Include stabilizing agents (glycerol, albumin) to maintain activity during storage

When reporting research with recombinant Adam15, researchers should clearly document the expression system, purification methods, and functional validation steps to ensure reproducibility across studies.

How can Adam15 research contribute to therapeutic strategies for abdominal aortic aneurysm?

Adam15 research reveals several potential therapeutic approaches for abdominal aortic aneurysm (AAA) based on its protective role in vascular wall integrity:

Potential Therapeutic Strategies:

• Upregulation of Adam15 expression or activity in the aortic wall

• Inhibition of the THBS1-cofilin pathway that becomes dysregulated in Adam15 deficiency

• Preservation of smooth muscle cell viability and contractile phenotype

• Reduction of F-actin depolymerization through targeting cofilin activation

The evidence supports Adam15 as a critical player in AAA pathology, with its decrease or loss triggering impaired function and loss of smooth muscle cells leading to adverse aortic remodeling and AAA formation. This provides novel insight into the molecular mechanisms of AAA—a potentially lethal disease that currently lacks effective medical therapy—and identifies potential therapeutic targets to prevent disease progression .

Future research should focus on developing methods to enhance Adam15 function specifically in vascular tissue and on identifying small molecules that can inhibit the downstream pathways activated by Adam15 deficiency, such as THBS1 upregulation or cofilin activation.

What are the key considerations when designing Adam15 knockout or knockdown experiments?

Researchers planning to manipulate Adam15 expression through knockout or knockdown approaches should consider several critical factors to ensure meaningful results:

Experimental Design Considerations:

• Model Selection:

  • Global knockout vs. conditional/tissue-specific knockout (using Cre-loxP systems)

  • Constitutional vs. inducible systems to control timing of Adam15 deletion

  • Cell-type specificity (endothelial-specific, smooth muscle-specific) to isolate cell-autonomous effects

• Validation Methods:

  • Confirm knockout/knockdown efficiency at both mRNA and protein levels

  • Assess potential compensatory upregulation of other ADAM family members

  • Verify functional consequences using integrin binding or cell adhesion assays

• Phenotypic Analysis:

  • Baseline characterization under normal conditions

  • Challenge with relevant stimuli (e.g., angiotensin II for vascular studies)

  • Comprehensive multi-tissue analysis to identify non-obvious phenotypes

• Control Selection:

  • Use littermate controls to minimize genetic background differences

  • Consider heterozygotes to assess gene dosage effects

  • Include wild-type controls treated with ADAM inhibitors for comparison

• Downstream Analysis:

  • Evaluate effects on THBS1-cofilin pathway activation

  • Assess cytoskeletal organization and smooth muscle cell function

  • Monitor integrin-mediated signaling pathways

When reporting knockout/knockdown studies, researchers should clearly document the specific method used, validation approach, genetic background of the models, and any compensatory mechanisms observed to ensure reproducibility and proper interpretation of results.

What techniques can reveal the structural basis of Adam15-integrin interactions?

Understanding the structural basis of Adam15-integrin interactions requires sophisticated structural biology approaches:

Structural Analysis Techniques:

• X-ray Crystallography:

  • Co-crystallization of the Adam15 disintegrin-like domain with integrin headpiece fragments

  • Analysis of RGD motif conformation within the binding pocket

  • Identification of key contact residues at the binding interface

• Cryo-Electron Microscopy:

  • Visualization of full-length Adam15-integrin complexes

  • Analysis of conformational changes upon binding

  • Study of larger complexes including additional binding partners

• Nuclear Magnetic Resonance (NMR):

  • Analysis of solution structure of smaller Adam15 domains

  • Investigation of dynamic changes during binding

  • Study of weak or transient interactions

• Molecular Dynamics Simulations:

  • Modeling of binding interactions based on known structures

  • Prediction of conformational changes during binding

  • Virtual screening of potential binding modulators

A putative binding model has been constructed based on the 3D structure of integrin αVβ3 in complex with cyclic RGD-containing peptides, suggesting that the RGD motif of Adam15 fits into a crevice between the propeller (α subunit) and βA (β subunit) domains . Further structural studies are needed to validate this model and determine whether there are differences in binding conformations between different integrin subtypes.

Researchers focusing on structural aspects should combine multiple complementary approaches and validate structural predictions with functional assays measuring binding affinity and specificity.

How does Adam15 expression correlate with vascular pathologies in different experimental models?

The relationship between Adam15 expression and vascular pathologies has been extensively studied across multiple experimental models, revealing consistent patterns:

Expression Patterns in Different Models:

These findings collectively suggest that Adam15 plays a protective role in vascular wall integrity, with its loss or reduction contributing to pathological vascular remodeling. The correlation between Adam15 expression and vascular pathologies is particularly relevant in the context of AAA, where Adam15 deficiency appears to be both a marker and a mechanistic contributor to disease progression.

Future research should focus on determining whether Adam15 expression levels could serve as a biomarker for AAA risk or progression, and whether therapeutic strategies aimed at restoring Adam15 function might prevent or slow AAA development in at-risk populations.

What are the methodological challenges in studying the disintegrin domain of recombinant Adam15?

Researchers investigating the disintegrin domain of recombinant Adam15 face several methodological challenges that require careful experimental design:

Challenge 1: Maintaining Proper Protein Folding

• The disintegrin-like domain contains 15 cysteine residues forming multiple disulfide bonds

• Incorrect disulfide bond formation can lead to misfolded protein with altered function

• Solution: Use mammalian or insect cell expression systems rather than bacterial systems; include oxidized/reduced glutathione during refolding

Challenge 2: Distinguishing RGD-dependent vs. RGD-independent Effects

• Adam15 can bind integrins through both RGD-dependent and RGD-independent mechanisms

• Difficulty isolating specific binding modes in functional studies

• Solution: Generate targeted mutations (RGD→AGD) and create chimeric proteins with disintegrin loops from other ADAMs to map binding specificity

Challenge 3: Recreating Physiological Context

• The disintegrin domain functions as part of a multi-domain protein in vivo

• Isolated domains may behave differently than in the context of the full protein

• Solution: Compare results from isolated domains with those from full-length protein; use domain deletion approaches

Challenge 4: Quantifying Binding Dynamics

• Traditional binding assays may not capture the dynamic nature of Adam15-integrin interactions

• Solution: Employ surface plasmon resonance (SPR) or biolayer interferometry (BLI) to measure association/dissociation kinetics

Challenge 5: Crystallization Difficulties

• The flexible nature of the disintegrin-like domain complicates crystallization

• Solution: Use fragment-based approaches; consider co-crystallization with binding partners to stabilize conformation

Addressing these challenges requires a multi-faceted approach combining structural biology, protein biochemistry, and cell biology techniques to comprehensively characterize the disintegrin domain's structure and function.

How do changes in Adam15 affect downstream signaling pathways in vascular smooth muscle cells?

Adam15 influences multiple signaling pathways in vascular smooth muscle cells, with its deficiency causing significant disruptions that contribute to cell dysfunction:

Affected Signaling Pathways:

• Growth and Proliferation Pathways:

  • Adam15 deficiency suppresses phosphorylation of ERK1/2 and Akt following angiotensin II stimulation

  • This reduction in signaling correlates with decreased cell proliferation as measured by BrdU incorporation

• Apoptosis Regulation:

  • Loss of Adam15 increases susceptibility to apoptosis in angiotensin II-treated cells

  • This may involve reduced survival signaling through Akt pathway disruption

• Cytoskeletal Regulation:

  • Adam15 deficiency increases THBS1 expression

  • Elevated THBS1 activates SSH1 phosphatase

  • SSH1 dephosphorylates (activates) cofilin

  • Activated cofilin promotes F-actin depolymerization to G-actin

  • Disrupted actin dynamics impair contractile function

• Contractile Protein Expression:

  • Adam15-deficient cells show reduced levels of contractile SMC proteins (SM22 and αSMC) following angiotensin II treatment

  • This reduction contributes to decreased contractile properties

• Migration Signaling:

  • Despite suppressed proliferation, Adam15-deficient SMCs exhibit enhanced migration rate in response to angiotensin II

  • This suggests differential regulation of migration vs. proliferation pathways

These signaling alterations collectively contribute to the vascular smooth muscle cell dysfunction observed in Adam15 deficiency, highlighting the importance of this protein in maintaining normal cell physiology and vascular wall integrity. Future research should focus on identifying the specific molecular mechanisms connecting Adam15 to these various signaling pathways.